TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03353025
Drug: dopamine agonist treatment
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
Study: NCT03881852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed orally, twice daily for up to 3 weeks
Study: NCT00538018
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01794767
Drug: 0,9% NaCl flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline solution
Study: NCT01794767
Drug: Heparin 50U/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin solution
Study: NCT02297594
Drug: AK0529
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK0529 capsule for oral administration
Study: NCT02297594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar placebo capsule for oral administration
Study: NCT02477072
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin doses will be administered according to the assigned group.
Study: NCT03143712
Drug: GLPG1690
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
Study: NCT01361308
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
Study: NCT01710007
Drug: 1PC002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
Study: NCT00707889
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours
Study: NCT00003582
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03387085
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03387085
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03387085
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study: NCT00482976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02965027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01759446
Drug: Placebo taken first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Study: NCT01759446
Drug: Generic H/A taken first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Study: NCT01759446
Drug: Vycavert taken first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Study: NCT01759446
Drug: Generic H/A plus i taken first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Study: NCT01759446
Drug: Generic H/A plus p taken first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Study: NCT01483365
Drug: Vaginal tablet Endometrin twice a day
Normalized name: Endometrin Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrin 100 mg twice a day
Study: NCT02734459
Drug: cataract surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery.
Study: NCT00354432
Drug: Placebo Pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive oral placebo pill.
Study: NCT01818011
Drug: GSK1322322 Initial fit for purpose tablets
Normalized name: Corona Multi-Purpose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
Study: NCT01818011
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
Study: NCT01818011
Drug: GSK1322322 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
Study: NCT01818011
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
Study: NCT03218657
Drug: Androgens
Normalized name: ANDROGENS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgens take orally 80mg qd
Study: NCT02087865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00487656
Drug: ART-123
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6mg/ml ampule solution for injection @ .01mg/kg
Study: NCT00487656
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/ml ampule solution for injection at .01mg/kg
Study: NCT00240396
Drug: Narcotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03419923
Drug: two stage regional citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
Study: NCT03419923
Drug: one stage regional citrate
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
Study: NCT04646044
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Treatment for COVID-19 Infection
Study: NCT00882804
Drug: placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
Study: NCT01001195
Drug: AGN-210669 ophthalmic solution, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Study: NCT01001195
Drug: AGN-210669 ophthalmic solution, 0.075%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Study: NCT01001195
Drug: AGN-210669 ophthalmic solution, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Study: NCT00787358
Drug: ZT-031
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 ul subcutaneous injection per day
Study: NCT05109143
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg Indomethacin Suppository administered at the time of Induction
Study: NCT02170103
Drug: Microbubbles
Approvals — FDA: no, EMA: no, PMDA: no
Description: The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.
Study: NCT02367833
Drug: Contraceptive Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
Study: NCT01469377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied in capsules
Study: NCT03393988
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After induction of general anesthesia; Fentanyl infusion (0.5 µg/kg/hr) will be started (which will be afterwards adjusted intraoperatively according to the hemodynamics and Bispectral Index (BIS) reading).
Study: NCT02203968
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
Study: NCT00478023
Drug: CG5503 IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg; 4 - 6 hourly; Total 72 hours
Study: NCT00478023
Drug: CG5503 IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg; 4 -6 hourly; Total 72 hours
Study: NCT00478023
Drug: CG5503 IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, 4 - 6 hourly; Total 72 hours
Study: NCT00478023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 - 6 hourly; Total 72 hours
Study: NCT02143388
Drug: IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
Study: NCT02753504
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04691076
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl is intravenously administrated
Study: NCT00611026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment will be once daily(QD) for 12 weeks.
Study: NCT04724109
Drug: Equfina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equfina oral tablets.
Study: NCT00251732
Drug: Double dose PPI plus evening placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg. twice daily with a placebo
Study: NCT03229980
Drug: Cold blood cardioplegia (large volume)
Normalized name: NEBULIZER,LARGE VOLUME #1770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg
Study: NCT03229980
Drug: Cold blood cardioplegia (small volume)
Normalized name: BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
Study: NCT03725891
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study: NCT00904592
Drug: Qi ming granula
Normalized name: Saxifraga granulata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
Study: NCT00904592
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: Basic therapy ＆ placebo~1. Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~2. placebo,Usage: 4.5g，po，tid
Study: NCT01405144
Drug: 5-fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluoruracil cream, twice a day, during 3 weeks
Study: NCT00606593
Drug: ACT-078573 oral capsules at 25 and 100 mg and matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
Study: NCT00606593
Drug: ACT-078573 and matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
Study: NCT00986037
Drug: ABT-308
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV doses
Study: NCT00986037
Drug: ABT-308
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple SC doses x 3
Study: NCT00986037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose
Study: NCT00986037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple SC doses x 3
Study: NCT00973232
Drug: Zaldiar®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
Study: NCT00973232
Drug: Ultracet®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
Study: NCT00973232
Drug: Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
Study: NCT00973232
Drug: Zaldiar®, multiple doses,(fed & fasting):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
Study: NCT00973232
Drug: Ultracet®, multiple doses, (fed & fasting)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
Study: NCT00656669
Drug: doxorubicin and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
Study: NCT01553708
Drug: Silver zinc sulfadiazine cream
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
Study: NCT01093235
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01093235
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00888719
Drug: CWP-0403 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
Study: NCT00888719
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks
Study: NCT00888719
Drug: CWP-0403 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
Study: NCT00000596
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02602210
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.
Study: NCT02602210
Drug: NaCL 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
Study: NCT00000426
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01120964
Drug: Intravenous L-Citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01120964
Drug: Placebo of Intravenous L-Citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
Study: NCT01003769
Drug: R-(-)-Gossypol Acetic Acid
Normalized name: citronellol acetate, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02066909
Drug: 0.15 mg PF-06649751
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
Study: NCT02066909
Drug: 0.5 mg PF-06649751
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
Study: NCT02066909
Drug: 0.5 mg PF-06649751
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
Study: NCT02840461
Drug: Placebo/Vehicle cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02066909
Drug: 1.5 mg PF-06649751
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
Study: NCT02066909
Drug: 1.5 mg PF-06649751 21 Days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
Study: NCT02066909
Drug: 3.0 mg PF-06649751
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
Study: NCT02944487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT02066909
Drug: 5.0 mg PF-06649751
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
Study: NCT02066909
Drug: 8.0 mg PF-06649751
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
Study: NCT02687815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
Study: NCT00802945
Drug: NKTR-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-102 given on a q14 day schedule
Study: NCT00802945
Drug: NKTR-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-102 given on a q21 day schedule
Study: NCT04114461
Drug: HL-TOF tab. 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL-TOF
Study: NCT04114461
Drug: Xeljanz tab. 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xeljanz
Study: NCT02357771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Study: NCT02179580
Drug: Xiang-Sha-Liu-Jun-Zi-Tang
Normalized name: Calagel Reformulated Jun 2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
Study: NCT02179580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
Study: NCT00487461
Drug: Simvastatin 40 mg
Normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing two doses of Simvastatin to placebo
Study: NCT00487461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT00487461
Drug: Simvastatin 80 mg
Normalized name: simvastatin 80 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing two doses of Simvastatin to placebo
Study: NCT04077879
Drug: ASP1617
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04077879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01288885
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01288885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03714152
Drug: ABI-H2158
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg or 25 mg tablets
Study: NCT03714152
Drug: Placebo for ABI-H2158
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic the ABI-H2158 5 mg or 25 mg tablets
Study: NCT00171262
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no